Additionally, the 36-month beta value for KZIA is 2.29. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for KZIA is 2.91M and currently, short sellers hold a 3.11% ratio of that float. The average trading volume of KZIA on March 10, 2025 was 1.95M shares.
KZIA) stock’s latest price update
Kazia Therapeutics Limited ADR (NASDAQ: KZIA)’s stock price has soared by 39.63 in relation to previous closing price of 0.85. Nevertheless, the company has seen a gain of 38.59% in its stock price over the last five trading days. prnewswire.com reported 2025-01-30 that SYDNEY, Jan. 30, 2025 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting this highly aggressive and treatment-resistant type of breast cancer.
KZIA’s Market Performance
Kazia Therapeutics Limited ADR (KZIA) has experienced a 38.59% rise in stock performance for the past week, with a -15.71% drop in the past month, and a -76.11% drop in the past quarter. The volatility ratio for the week is 22.60%, and the volatility levels for the past 30 days are at 14.58% for KZIA. The simple moving average for the past 20 days is 28.67% for KZIA’s stock, with a -65.16% simple moving average for the past 200 days.
Analysts’ Opinion of KZIA
Many brokerage firms have already submitted their reports for KZIA stocks, with Maxim Group repeating the rating for KZIA by listing it as a “Buy.” The predicted price for KZIA in the upcoming period, according to Maxim Group is $3 based on the research report published on February 06, 2025 of the current year 2025.
Maxim Group, on the other hand, stated in their research note that they expect to see KZIA reach a price target of $18. The rating they have provided for KZIA stocks is “Buy” according to the report published on October 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to KZIA, setting the target price at $17 in the report published on January 05th of the previous year.
KZIA Trading at -18.71% from the 50-Day Moving Average
After a stumble in the market that brought KZIA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.53% of loss for the given period.
Volatility was left at 14.58%, however, over the last 30 days, the volatility rate increased by 22.60%, as shares sank -21.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.93% lower at present.
During the last 5 trading sessions, KZIA rose by +38.60%, which changed the moving average for the period of 200-days by -58.19% in comparison to the 20-day moving average, which settled at $0.9171. In addition, Kazia Therapeutics Limited ADR saw -33.33% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for KZIA
Current profitability levels for the company are sitting at:
- 1.0 for the gross margin
The net margin for Kazia Therapeutics Limited ADR stands at -11.6. Equity return is now at value -2639.52, with -106.15 for asset returns.
Based on Kazia Therapeutics Limited ADR (KZIA), the company’s capital structure generated -0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -15.11.
Currently, EBITDA for the company is -26.77 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 2.25. The receivables turnover for the company is 17.35for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.24.
Conclusion
In conclusion, Kazia Therapeutics Limited ADR (KZIA) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
